Ribavirin  (Synonyms: Ribasphere; ICN-1229)

Ribavirin (GMP) is Ribavirin (HY-B0434) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV. Ribavirin also has anti-orthopoxvirus and anti-variola activities.

用 5、10 和 20 μM Ribavirin GMP (ICN-1229) 处理 LPS 刺激的小胶质细胞可诱导 NO₂ 水平降低 43% (p<0.05)、53% (p<0.05) 和 59 % (p<0.05)。
Ribavirin GMP (ICN-1229) (10 mM) 在非刺激培养物中不显著降低细胞表面积，但在 LPS 刺激的小胶质细胞中显著降低细胞表面积 (32%，p<0.05)^[3]。
Ribavirin GMP (ICN-1229) 对 DENV 具有活性，在 A549 细胞中的 EC₅₀ 为 3 μM，CM-10-18 与 Ribavirin GMP (ICN-1229) 的组合在减少病毒复制^[4]。
Ribavirin (20 μM, 7 天) 抑制丙型肝炎病毒 (HCV) 在由人类 iPSC 细胞发育而成的功能性肝细胞样细胞中的复制^[6]。
Ribavirin (1, 10, 25 μg/mL, 72 小时) 通过调节凋亡调控基因，减弱 ZILV 诱导的 hNPCs 细胞凋亡，并通过 PI3K/AKT 通路促进存活信号传导^[7]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

ALT、AST 活性和胆红素水平通过 JAT 联合干扰素和 Ribavirin GMP (ICN-1229) 给药显著降低 (p<0.01)。JAT、干扰素或 Ribavirin GMP 单独与 CCl₄ 一起使用时，肝脏似乎对 CCl₄ 表现出一定的肝脏保护作用，这可以通过正常肝索的存在、无坏死和较少脂肪来证明浸润。用 JAT、聚乙二醇干扰素和 Ribavirin GMP (ICN-1229) 单独或联合处理的组显示 TGF-β 和 Bax 的表达减少。在干扰素、Ribavirin GMP (ICN-1229) 和JAT三联处理组中，p53的表达水平明显降低^[1]。
Ribavirin GMP (ICN-1229) 胶囊 (400 毫克 Ribavirin GMP) 处理的 Wistar 大鼠在血清和肝脏水平显示激活素 A 显著减少和卵泡抑素显著增加。只有当 Ribavirin GMP 与 IFN-α 或 Peg-IFN-α 联合使用时，Ribavirin GMP (ICN-1229) 才具有很强的抗病毒活性^[2]。
Ribavirin GMP (40 mg/kg，po) 显著提高 CM-10-18 在小鼠体内的抗病毒功效。Ribavirin GMP (ICN-1229) 可抑制培养细胞中的 DENV 病毒感染，但单药处理对降低病毒血症无效^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

244.20

C₈H₁₂N₄O₅

36791-04-5

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Robert O Baker, et al. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res. 2003 Jan;57(1-2):13-23.  [Content Brief]

  [2]. Abdel-Hamid NM, et al. Synergistic Effects of Jerusalem Artichoke in Combination with Pegylated Interferon Alfa-2a and Ribavirin Against Hepatic Fibrosis in Rats. Asian Pac J Cancer Prev. 2016;17(4):1979-85.  [Content Brief]

  [3]. Refaat B, et al. The effects of pegylated interferon-α and ribavirin on liver and serum concentrations of activin-A and follistatin in normal Wistar rat: a preliminary report. BMC Res Notes. 2015 Jun 26;8:265  [Content Brief]

  [4]. Savic D, et al. Ribavirin shows immunomodulatory effects on activated microglia. Immunopharmacol Immunotoxicol. 2014 Dec;36(6):433-41  [Content Brief]

  [5]. Chang J, et al. Combination of α-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo. Antiviral Res. 2011 Jan;89(1):26-34  [Content Brief]

  [6]. Sa-Ngiamsuntorn K, et al. A robust model of natural hepatitis C infection using hepatocyte-like cells derived from human induced pluripotent stem cells as a long-term host. Virol J. 2016 Apr 5;13:59.  [Content Brief]

  [7]. Kim JA, Seong RK, Kumar M, Shin OS. Favipiravir and Ribavirin Inhibit Replication of Asian and African Strains of Zika Virus in Different Cell Models. Viruses. 2018 Feb 9;10(2):72.  [Content Brief]